Corpus Intelligence IC Memo — ARISE AUSTIN MEDICAL CENTER 2026-04-26 21:26 UTC
IC Memo — ARISE AUSTIN MEDICAL CENTER
Investment Committee Memorandum | TX | 21 beds | Grade F | EBITDA uplift $1.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ARISE AUSTIN MEDICAL CENTER

CCN 450871 | TRAVIS, TX | 21 beds | April 26, 2026
EBITDA BridgeData Room
F
Investability

1. Target Overview & Investment Thesis

ARISE AUSTIN MEDICAL CENTER is a 21-bed community hospital in TRAVIS, TX with $24.6M in net patient revenue and a 2.7% operating margin. The hospital serves a payer mix of 13.1% Medicare, 0.0% Medicaid, and 86.9% commercial.

Thesis: Turnaround. Our ML models identify $1.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 2.7% to 10.1% (+736bps).

Net Revenue HCRIS$24.6M
Current EBITDA COMPUTED$661K
Operating Margin COMPUTED2.7%
Occupancy HCRIS7.4%
Revenue / Bed COMPUTED$1.2M
Net-to-Gross HCRIS17.3%
Distress Probability MLnan%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
228
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of 2.7% places it above the state median. Among 228 size-comparable peers (10-42 beds), the median margin is -9.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (10-42), prioritizing same-state peers. 228 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ARISE AUSTIN MEDICAL CENTER (Target)TX21$24.6M2.7%
WISE HEALTH SYSTEM - PARKWAYTX36$361.0M-15.5%
CORYELL MEMORIAL HOSPITALTX25$305.9M-1.5%
TEXAS ORTHOPEDIC HOSPITATX42$237.8M46.3%
METHODIST HOSPITAL FOR SURGERYTX32$178.4M22.8%
TEXAS SPINE AND JOINT HOSPITALTX20$147.3M30.3%
NORTH CENTRAL SURGICAL HOSPITATX24$143.6M32.0%
SCOTT AND WHITE HOSPITAL TAYLOTX25$139.7M-47.5%
BAYLOR SURGICAL HOSPITAL AT FOTX30$136.0M14.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$516K+210bp18mo
Cost to Collect4.5%2.5%$491K+200bp12mo
Denial Rate Reduction12.0%6.5%$486K+198bp12mo
A/R Days Reduction5200.0%3800.0%$299K+122bp9mo
Clean Claim Rate88.0%96.0%$16K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$516K
Cost to Collect
$491K
Denial Rate Reduction
$486K
A/R Days Reduction
$299K
Clean Claim Rate
$16K
Total EBITDA Uplift$1.8M
Current EBITDA$661K
+ RCM Uplift+$1.8M
Pro Forma EBITDA$2.5M
Current Margin2.7%
Pro Forma Margin10.1%
WC Released (1x)$942K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$1.0M$22.4M22.07x85.7%
Base (11x exit)10.0x11.0x$1.0M$25.0M24.60x89.8%
Bull Case9.0x11.0x$915K$31.3M34.21x102.7%
Bull (12x exit)9.0x12.0x$915K$34.4M37.61x106.6%
Bear Case11.0x10.0x$1.1M$13.1M11.68x63.5%
Bear (11x exit)11.0x11.0x$1.1M$14.7M13.18x67.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 7.4%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 228 hospitals with 10-42 beds
  • Same-state prioritization (n=229)
  • Comp margins: P25=-40.1% / P50=-9.3% / P75=9.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.